Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00685936PMID 8194169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

  2004cited by this paper
• The chemotherapy of posterior Fossa tumors in childhood

  2004cited by this paper
• Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.

  1993cited by this paper
• Enhancement of Nitrosourea Activity in Medulloblastoma and Glioblastoma Multiforme

  1992cited by this paper
• Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.

  1992cited by this paper
• Therapeutic analysis of in vitro and in vivo brain tumor models.

  1991cited by this paper
• Medulloblastoma: tumor biological and clinical perspectives

  1991cited by this paper
• Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.

  1990cited by this paper
• Development and characterization of pediatric osteosarcoma xenografts.

  1990cited by this paper
• The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial

  1989cited by this paper
• O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.

  1989cited by this paper
• Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma.

  1989cited by this paper
• Experimental chemotherapy of human medulloblastoma with classical alkylators.

  1986cited by this paper
• Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.

  1986cited by this paper
• A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line.

  1985cited by this paper
• Growth and characterization of childhood rhabdomyosarcomas as xenografts.

  1982cited by this paper
• Growth and Chemotherapeutic Response in Athymic Mice of Tumors Arising from Human Glioma‐derived Cell Lines

  1981cited by this paper
• High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children.

  1981cited by this paper
• The United States and the World

  1979cited by this paper
• In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

  1973cited by this paper
• A manual on quantitative drug evaluation in experimental tumor systems.

  1962cited by this paper
• A manual on quantitative drug evaluation in experimental tumor systems. I. Background, description of criteria, and presentation of quantitative therapeutic data on various classes of drugs obtained in diverse experimental tumor systems.

  1962cited by this paper

• Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform

  2025cites this paper
• Morphological profiling by Cell Painting in human neural progenitor cells classifies hit compounds in a pilot drug screen for Alzheimer’s disease

  2023cites this paper
• Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan

  2021cites this paper
• A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

  2021cites this paper
• Pharmacologic topoisomerase-I inhibition causes DNA damage and mortality in activated CD4+ T cells

  2018cites this paper
• Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

  2018cites this paper
• Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma

  2018cites this paper
• Major Contributions towards Finding a Cure for Cancer through Chemotherapy: A Historical Review

  2016cites this paper
• Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer

  2014cites this paper
• Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

  2013cites this paper
• Topoisomerase I Inhibitors, Shikonin and Topotecan, Inhibit Growth and Induce Apoptosis of Glioma Cells and Glioma Stem Cells

  2013cites this paper
• Induction of the Unfolded Protein Response Drives Enhanced Metabolism and Chemoresistance in Glioma Cells

  2013cites this paper
• Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors

  2013cites this paper
• DUKE UNIVERSITY MEDICAL CENTER CURRICULUM VITAE

  2013cites this paper
• The Pediatric Preclinical Testing Program

  2011cites this paper
• Affinity‐matured anti‐glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas

  2011cites this paper
• Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

  2010cites this paper
• Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.

  2010cites this paper
• Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study

  2009cites this paper
• Clinical pharmacology of camptothecins

  2009cites this paper
• Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain.

  2008cites this paper
• Molecular Characterization of the Pediatric Preclinical Testing Panel

  2008cites this paper
• Factors Influencing Topotecan CNS Penetration in Mouse Models

  2008influential citation
• Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.

  2007cites this paper
• Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.

  2007cites this paper
• Phase I/II study of IV topotecan in combination with whole brain radiation for the treatment of brain metastases

  2007cites this paper
• A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children’s oncology group

  2006cites this paper
• by a Tyrosine Kinase Inhibitor Topotecan Central Nervous System Penetration Is Altered

  2006influential citation
• Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.

  2006cites this paper
• Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.

  2006cites this paper
• Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

  2006cites this paper
• Topotecan by 21‐day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study

  2006cites this paper
• Clinical Pharmacology of Brain Tumor Chemotherapy

  2006cites this paper
• Convection-enhanced delivery of Ls-TPT enables an effective , continuous , low-dose chemotherapy against malignant glioma xenograft model 1

  2006cites this paper
• Topotecan Can Compensate for Protracted Radiation Treatment Time Effects in High Grade Glioma Xenografts*

  2005cites this paper
• A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma

  2005cites this paper
• Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

  2005cites this paper
• Has chemotherapy reached its limits in pediatric cancers?

  2005cites this paper
• Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI)

  2004cites this paper
• Topoisomerase I interactive drugs in children with cancer

  2004cites this paper
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cites this paper
• Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models

  2004cites this paper
• The Accumulation of Topotecan in 9L Glioma and in Brain Parenchyma with and without Dexamethasone Administration

  2004cites this paper
• The camptothecins.

  2003cites this paper
• Phase I Study of Topotecan in Combination with Concurrent Radiotherapy in Adults with Glioblastoma

  2003cites this paper
• The role of xenografting in pediatric brain tumor research with specific emphasis on medulloblastoma/primitive neuroectodermal tumors of childhood.

  2003cites this paper
• Nuevos quimioterápicos en Neurooncología

  2003cites this paper
• A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma

  2003cites this paper
• Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy.

  2003cites this paper
• Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study.

  2002cites this paper
• O 6-Benzylguanine-mediated Enhancement of Chemotherapy 1

  2002cites this paper
• Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience

  2002cites this paper
• Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study

  2002cites this paper
• O6-benzylguanine-mediated enhancement of chemotherapy.

  2002cites this paper
• Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.

  2002cites this paper
• Phase I S tudy o f T opotecan P lus C ranial R adiation f or Glioblastoma M ultiforme: R esults o f R adiation T herapy Oncology G roup T rial 9 507

  2001cites this paper
• Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

  2001cites this paper
• Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts

  2001cites this paper
• Topotecan–filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells

  2001cites this paper
• Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

  2001cites this paper
• Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.

  2001cites this paper
• Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

  2000cites this paper
• O6-Benzylguanine-mediated enhancement of nitrosourea activity in Mer− central nervous system tumor xenografts – implications for clinical trials

  2000cites this paper
• Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

  2000cites this paper
• Clinical Presentation, Diagnosis, and Pharmacotherapy of Patients with Primary Brain Tumors

  1999cites this paper
• Chemotherapy for adults with malignant glioma.

  1999cites this paper
• Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines

  1999cites this paper
• Topotecan for the Treatment of Recurrent or Progressive Central Nervous System Tumors – A Pediatric Oncology Group Phase II Study

  1999cites this paper
• Comparative brain tissue distribution of camptothecin and topotecan in the rat

  1999cites this paper
• Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.

  1999cites this paper
• Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

  1999cites this paper
• Topotecan treatment of adults with primary malignant glioma

  1999cites this paper
• Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors

  1998cites this paper
• Topoisomerase I inhibitors and drug resistance

  1998cites this paper
• Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.

  1998cites this paper
• Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.

  1998cites this paper
• Conduct of phase I trials in children with cancer.

  1998cites this paper
• Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.

  1998cites this paper
• Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.

  1998cites this paper
• Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.

  1998cites this paper
• Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

  1998cites this paper
• DNA-topoisomerase I, a new target for the treatment of neuroblastoma.

  1997cites this paper
• Topotecan, an active new antineoplastic agent: review and current status.

  1997cites this paper
• Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.

  1997cites this paper
• Pharmacokinetic Optimisation of Cancer Chemotherapy

  1997cites this paper
• Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

  1997cites this paper
• Schedule‐dependent Efficacy of Camptothecins in Models of Human Cancer a

  1996cites this paper
• The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation

  1996cites this paper
• Phase II evaluation of topotecan for pediatric central nervous system tumors.

  1996cites this paper
• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts

  1996cites this paper
• Current perspectives on camptothecins in cancer treatment.

  1996cites this paper
• Treatment of Central Nervous System Xenografts with Camptothecins

  1996cites this paper
• Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors

  1995cites this paper